Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans

PLoS Neglected Tropical Diseases

Volumn 3, Issue 11, 2009, Pages

  Müller, Thomas ^a   Dietzschold, Bernhard ^b   Ertl, Hildegund ^c   Fooks, Anthony R ^d   Freuling, Conrad ^a   Fehlner Gardiner, Christine ^e   Kliemt, Jeannette ^a   Meslin, Francois X ^f   Rupprecht, Charles E ^g   Tordo, Noël ^h   Wanderler, Alexander I ^e   Kieny, Marie Paule ^f  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c WISTAR INSTITUTE   (United States)

^d VETERINARY LABORATORIES AGENCY   (United Kingdom)

^e Ottawa Laboratory Fallowfield   (Canada)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MOUSE MONOCLONAL ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SPECIFICITY; EPITOPE MAPPING; FEMALE; HYBRIDOMA; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; RABIES; RABIES VIRUS; ANIMAL; CELL LINE; DRUG EFFECT; ECONOMICS; ENZYMOLOGY; EVALUATION; HAMSTER; HUMAN; IMMUNOLOGY; METHODOLOGY; MOUSE; PROPHYLAXIS; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; CRICETINAE; HUMANS; MICE; NEUTRALIZATION TESTS; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VIRUS;

EID: 73449088331     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000542     Document Type: Article

References (50)

1. Badrane H, Bahloul C, Perrin P, Tordo N (2001) Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 75: 3268-3276.
2. Kuzmin IV, Hughes GJ, Botvinkin AD, Orciari LA, Rupprecht CE (2005) Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for lyssavirus genotype definition. Virus Res 111: 28-43.
3. Kuzmin IV, Wu X, Tordo N, Rupprecht CE (2008) Complete genomes of Aravan, Khujand, Irkut and West Caucasian bat viruses, with special attention to the polymerase gene and non-coding regions. Virus Res 136: 81-90.
4. WHO (2005) WHO Expert Consultation on Rabies, First Report, WHO Technical Report Series 931, Geneva: World Health Organization.
5. Knobel DL, Cleaveland S, Coleman PG, Fèvre EM, Meltzer MI, et al. (2005) Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83: 360-368.
6. Fooks AR (2005) Rabies remains a 'neglected disease'. Eurosurveillance 10: 211-212.
7. Mallewa M, Fooks AR, Banda D, Chikungwa P, Mankhambo L, et al. (2007) Rabies encephalitis in malaria-endemic area, Malawi, Africa. Emerg Infect Dis 13: 136-139.
8. Tang X, Luo M, Zhang S, Fooks AR, Hu R, et al. (2005) Pivotal role of dogs in rabies transmission, China. Emerg Infect Dis 11: 1970-1972.
9. Dietzschold B, Kao M, Zheng YM, Chen ZY, Maul G, et al. (1992) Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A 89: 7252-7256. Erratum in: Proc Natl Acad Sci U S A 89: 9365.
10. Lafon M, Wiktor TJ, Macfarlan RI (1983) Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J Gen Virol 64: 843-851.
11. Schumacher CL, Dietzschold B, Ertl HC, Niu HS, Rupprecht CE, et al. (1989) Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest 84: 971-975.
12. Dietzschold B (1994) Monoclonal antibodies in rabies therapy. Clin Immunother 1: 245-249.
13. WHO (1997) WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. Geneva: World Health Organization: WHO/EMC/ZOO/96.6.
14. Wilde H, Chomchey P, Punyaratabandhu P, Phanupak P, Chutivongse S (1989) Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin. Bull World Health Organ 67: 731-736.
15. Wilde H, Chomchey P, Prakongsri S, Puyaratabandhu P, Chutivongse S (1989) Adverse effects of equine rabies immune gobulin. Vaccine 7: 10-11.
16. Champion JM, Kean RB, Rupprecht CE, Notkins AL, Koprowski H, et al. (2000) The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 235: 81-90.
17. Macek C (1982) Monoclonal antibodies: key to a revolution in clinical medicine. JAMA 247: 2463-2470.
18. Chan CEZ, Chan AHY, Hanson BJ, Ooi EE (2009) The use of antibodies in the treatment of infectious diseases. Singapore Med J 50: 663-672.
19. Siberil S, Teillaud JL (2004) Future prospects in antibody engineering and therapy. In: Subramanian G, ed.Volume 2: Novel Technologies and Therapeutic Use. New York: Springer. pp 199-205.
20. Dietzschold B, Gore M, Casali P, Ueki Y, Rupprecht CE, et al. (1990) Biological characterization of human monoclonal antibodies to rabies virus. J Virol 64: 3087-3090.
21. Dorfman N, Dietzschold B, Kajiyama W, Fu ZF, Koprowski H, et al. (1994) Development of human monoclonal antibodies to rabies. Hybridoma 13: 397-402.
22. Rando RF, Notkins AL (1994) Production of human monoclonal antibodies against rabies virus. Curr Top Microbiol Immunol 187: 195-205.
23. Hanlon CA, DeMattos CA, DeMattos CC, Niezgoda M, Hooper DC, et al. (2001) Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19: 3834-3842.
24. Sloan SE, Hanlon C, Weldon W, Niezgoda M, Blanton J, et al. (2007) Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25: 2800-2810.
25. Muhamuda K, Madhusudana SN, Ravi V (2007) Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies. Hum Vaccin 3: 192-195.
26. Jallet C, Jacob Y, Bahloul C, Drings A, Desmezières E, et al. (1999) Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol 73: 225-233.
27. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, et al. (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies viru variants and individual in vitro escape mutants. J Virol 79: 9062-9068.
28. Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, et al. (2006) Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 193: 796-801.
29. Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, et al. (2008) First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26: 5922-5927.
30. Smith JS, Yager PA, Baer GM (1973) A rapid reproducible test for determining rabies neutralizing antibodies. Bull World Health Org 48: 535-541.
31. Cliquet F, Aubert M, SagnéL (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J ImmunolMethods 212: 79-87.
32. Geue L, Schares S, Schnick C, Kliemt J, Beckert A, et al. (2008) Genetic characterisation of attenuated SAD rabies virus strains used for oral vaccination of wildlife. Vaccine 26: 3227-3235.
33. Desmézières E, Maillard A, Gaudin Y, Tordo N, Perrin P (2003) Differential stability and fusion activity of Lyssavirus glycoprotein trimers. Virus Res 91: 181-187.
34. Nagarajan T, Reddy GS, Mohana Subramanian B, Rajalakshmi S, Thiagarajan D, et al. (2006) A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. Biologicals 34: 21-27.
35. Schneider LG, Barnard BJH, Schneider HP Odegaard OA, Müller J, et al. (1985) Application of monoclonal antibodies for epidemiological investigations and oral vaccination studies. In: Kuwert E, Merieux C, Koprowski H, Bögel K, eds. Rabies in the Tropics. Berlin: Springer. pp 47-59.
36. Dietzschold B, Tollis M, Lafon M, Wunner WH, Koprowski H (1987) Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology 161: 29-36.
37. Cox JH, Schneider LG (1976) Prophylactic immunization of humans against rabies by intradermal inoculation of human diploid cell culture vaccine. J Clin Microbiol 3: 96-101.
38. Hanlon CA, Kuzmin IV, Blanton JD, Weldon WC, Manangan JS, et al. (2005) Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res 111: 44-54.
39. Dean DJ, Abelseth MK, Athanasiu P (1996) The fluorescence antibody test. In: Meslin FX, Kaplan MM, Koprowski H, eds. Laboratory techniques in rabies. Geneva: World Health Organization. pp 88-93.
40. Olsson L, Kaplan HS (1980) Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci U S A 77: 5429-5431.
41. de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, et al. (2007) A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58: 359-368.
42. Morimoto K, Schnell MJ, Pulmanausahakul R, McGettigan JP, Foley HD (2001) High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods 252: 199-206.
43. Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, et al. (2003) Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 188: 53-56.
44. Waldman TA, Strober W, Blaese RM (1970) In: Merler E, ed. Immunoglobulins. Washington: National Academy of Science. 33 p.
45. Brookes SM, Parsons G, Johnson N, McElhinney LM, Fooks AR (2005) Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 23: 4101-4109.
46. Dietzschold B, Wiktor TJ, Wunner WH, Varrichio A (1983) Chemical and immunological analysis of the rabies soluble glycoprotein. Virology 124: 330-337.
47. Wiktor TJ, Macfarlan RI, Foggin CM, Koprowski H (1984) Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand 57: 199-211.
48. Lafon M, Edelman L, Bouvet JP, Lafage M, Montchâ tre E (1990) Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol 71: 1689-1696.
49. Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13: 1619-1633.
50. Dietzschold B, Rupprecht CE, Tollis M, Lafon M, Mattei J, et al. (1988) Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related viruses: implications for epidemiology and control of rabies. Rev Infect Dis 10 (Suppl 4): 785-798.